

Julian Panes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4775763/publications.pdf>

Version: 2024-02-01

266
papers

25,805
citations

7551

77
h-index

7333

152
g-index

280
all docs

280
docs citations

280
times ranked

22873
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 85-96.	0.9	7
2	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 26-31.	0.6	48
3	Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 234-245.	0.9	11
4	Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 444-451.	0.6	4
5	Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 17-27.	3.7	44
6	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	0.9	5
7	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 464-478.	1.9	73
8	INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1737-1745.	0.9	19
9	Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity. <i>European Radiology</i> , 2022, 32, 3334-3345.	2.3	11
10	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 294-306.	3.7	42
11	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	0.6	88
12	Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210796.	1.5	4
13	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. <i>Gastroenterology</i> , 2022, 162, 1891-1910.	0.6	28
14	Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel (Mesenchymal Stem) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Controlled Trial. <i>Diseases of the Colon and Rectum</i> , 2022, 65, 713-720.	0.7	45
15	Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2337-2346.e3.	2.4	20
16	Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: <sc>ERELATE</sc> Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 463-476.	1.9	12
17	Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. <i>Lancet, The</i> , 2022, 399, 2113-2128.	6.3	187
18	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. <i>Lancet, The</i> , 2022, 399, 2031-2046.	6.3	105

#	ARTICLE	IF	CITATIONS
19	Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 983-993.	0.9	6
20	Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1130-1141.	0.6	37
21	Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin) Tj ETQq1 1 0.784314 rgBT /Overlock 816-825.	0.9	18
22	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
23	Dissecting Common and Unique Effects of Anti-Î±4Î²7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 441-452.	0.6	17
24	Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 950-959.	0.6	42
25	Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1963-1967.	0.9	0
26	Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1852-1863.	0.6	16
27	Development of a Highly Sensitive Ultra-High-Performance Liquid Chromatography Coupled to Electrospray Ionization Tandem Mass Spectrometry Quantitation Method for Fecal Bile Acids and Application on Crohn's Disease Studies. <i>Journal of Agricultural and Food Chemistry</i> , 2021, 69, 5238-5251.	2.4	24
28	Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1999-2009.	0.9	12
29	Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2001-2010.	0.6	27
30	Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2022-2030.	0.6	28
31	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021, 9, 766-772.	1.6	22
32	Ulcerative colitis: shedding light on emerging agents and strategies in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 931-946.	1.9	9
33	Integrin Inhibitors in Inflammatory Bowel Disease: From Therapeutic Antibodies to Small-Molecule Drugs. <i>Gastroenterology</i> , 2021, 161, 1791-1793.	0.6	2
34	Letter: accuracy of magnetic resonance index of activity score to predict response to biologics in Crohn's disease—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 207-208.	1.9	0
35	Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 271-280.	1.9	65
36	Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 550-561.	0.6	144

#	ARTICLE	IF	CITATIONS
37	El registro ENEIDA (Estudio Nacional en Enfermedad Inflamatoria intestinal sobre Determinantes) Tj ETQq1 1 0.784314 rgBT /Overlock 1 HepatologĀa, 2020, 43, 551-558.	0.2	33
38	JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. Journal of Crohn's and Colitis, 2020, 14, S711-S712.	0.6	4
39	Pre-treatment magnetic resonance enterography findings predict the response to TNF-α inhibitors in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1563-1573.	1.9	29
40	Integrated microbiota and metabolite profiles link Crohn's disease to sulfur metabolism. Nature Communications, 2020, 11, 4322.	5.8	79
41	Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 997-998.	1.9	2
42	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1209-1210.	1.9	1
43	Controlling leukocyte trafficking in IBD. Pharmacological Research, 2020, 159, 105050.	3.1	14
44	Validation of the Simplified Magnetic Resonance Index of Activity [sMARIA] Without Gadolinium-enhanced Sequences for Crohn's Disease. Journal of Crohn's and Colitis, 2020, 14, 1074-1081.	0.6	26
45	Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology, 2020, 158, 2139-2149.e14.	0.6	171
46	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology, 2020, 158, 2123-2138.e8.	0.6	189
47	Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease. Gastroenterology, 2019, 157, 432-439.e1.	0.6	113
48	Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis. Advances in Therapy, 2019, 36, 3503-3518.	1.3	33
49	Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Alimentary Pharmacology and Therapeutics, 2019, 50, 1068-1076.	1.9	132
50	Tu1717 " Tofacitinib for the Treatment of Ulcerative Colitis: Up to 5.4 Years of Safety Data from Global Clinical Trials. Gastroenterology, 2019, 156, S-1097.	0.6	2
51	Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. Gastroenterology, 2019, 157, 1233-1244.e5.	0.6	58
52	Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. Alimentary Pharmacology and Therapeutics, 2019, 49, 265-276.	1.9	28
53	Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn's Disease Patients. Frontiers in Immunology, 2019, 10, 1244.	2.2	29
54	Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. GastroenterologĀa Y HepatologĀa, 2019, 42, 403-412.	0.2	20

#	ARTICLE	IF	CITATIONS
55	Five-year Safety Data From OPUS, a European Observational Safety Registry for Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] or Conventional Therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1148-1157.	0.6	10
56	Assessment of Crohn's disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. <i>Gut</i> , 2019, 68, 1115-1126.	6.1	178
57	Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1541-1550.	2.4	191
58	Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481987420.	1.4	5
59	Differences in Peripheral and Tissue Immune Cell Populations Following Haematopoietic Stem Cell Transplantation in Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 634-647.	0.6	13
60	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1673-1679.e1.	2.4	26
61	Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2019, 25, 1764-1774.	1.4	6
62	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 476-488.	0.6	43
63	Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 600-609.	0.6	48
64	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 687-694.	0.6	10
65	Comparison of Capsule Endoscopy and Magnetic Resonance Enterography for the Assessment of Small Bowel Lesions in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 775-780.	0.9	56
66	Is the Objective of Treatment for Crohn's Disease Mucosal or Transmural Healing?. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1037-1039.	2.4	9
67	Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 440-449.	0.9	47
68	Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1334-1342.e4.	0.6	331
69	Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 76-87.	0.6	34
70	14 POST-HOC ANALYSIS OF TOFACITINIB CROHN'S DISEASE PHASE 2 INDUCTION EFFICACY IN SUBGROUPS WITH BASELINE ENDOSCOPIC OR BIOMARKER EVIDENCE OF INFLAMMATION. <i>Gastroenterology</i> , 2018, 154, S81.	0.6	10
71	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	6.1	108
72	Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 145-156.	0.6	80

#	ARTICLE	IF	CITATIONS
73	Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review. <i>World Journal of Gastroenterology</i> , 2018, 24, 4821-4834.	1.4	59
74	Mesenchymal stromal cells in the treatment of perianal fistulas in Crohn's disease. <i>Immunotherapy</i> , 2018, 10, 1203-1217.	1.0	11
75	Persistent damage on magnetic resonance enterography in patients with Crohn's disease in endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1232-1241.	1.9	30
76	Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 671-680.	3.7	126
77	Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S633-S640.	0.6	20
78	Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1158-1169.	0.6	95
79	Can we Monitor a Patient with Inflammatory Bowel Disease and Adapt Treatment without Endoscopy?. <i>Current Drug Targets</i> , 2018, 19, 777-781.	1.0	4
80	Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade] or Conventional Therapy. <i>Journal of Crohn's and Colitis</i> , 2017, 11, j1w221.	0.6	51
81	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017, 66, 1049-1059.	6.1	274
82	Alterations in the epithelial stem cell compartment could contribute to permanent changes in the mucosa of patients with ulcerative colitis. <i>Gut</i> , 2017, 66, 2069-2079.	6.1	158
83	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet</i> , 2017, 389, 1699-1709.	6.3	364
84	Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents. <i>BioDrugs</i> , 2017, 31, 223-237.	2.2	30
85	Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest. <i>Gastroenterology</i> , 2017, 152, S1308-S1309.	0.6	77
86	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	13.9	1,232
87	Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1161-1168.	0.6	56
88	New treatment strategies for ulcerative colitis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 963-973.	1.3	36
89	Association between disease activity and quality of life in ulcerative colitis: Results from the CRONICA study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1818-1824.	1.4	16
90	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 377, 496-497.	13.9	102

#	ARTICLE	IF	CITATIONS
91	Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1335-1346.	0.6	44
92	Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 652-664.	8.2	178
93	Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2017, 152, 362-373.e3.	0.6	70
94	Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 246-255.	0.6	19
95	Comparison of three magnetic resonance enterography indices for grading activity in Crohn's disease. <i>Journal of Gastroenterology</i> , 2017, 52, 585-593.	2.3	83
96	Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e126.	1.3	10
97	Increasing efficiency of MRE for diagnosis of Crohn's disease activity through proper sequence selection: a practical approach for clinical trials. <i>Abdominal Radiology</i> , 2017, 42, 2783-2791.	1.0	23
98	Commensal-Specific CD4+ Cells From Patients With Crohn's Disease Have a T-Helper 17 Inflammatory Profile. <i>Gastroenterology</i> , 2016, 151, 489-500.e3.	0.6	75
99	Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1310-1315.	0.6	16
100	Central Endoscopy Reading in Inflammatory Bowel Diseases: Table 1.. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S542-S547.	0.6	18
101	Nanoencapsulated budesonide in self-stratified polyurethane-polyurea nanoparticles is highly effective in inducing human tolerogenic dendritic cells. <i>International Journal of Pharmaceutics</i> , 2016, 511, 785-793.	2.6	14
102	The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, e121-e122.	2.4	3
103	Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. <i>Lancet, The</i> , 2016, 388, 1281-1290.	6.3	771
104	Small Bowel Imaging: an Update. <i>Current Gastroenterology Reports</i> , 2016, 18, 39.	1.1	2
105	Response to Gracie and Ford. <i>American Journal of Gastroenterology</i> , 2016, 111, 901-902.	0.2	0
106	Diagnostic Performance of the Simple Clinical Colitis Activity Index Self-Administered Online at Home by Patients With Ulcerative Colitis: CRONICA-UC Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 261-268.	0.2	42
107	Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2051-2059.	1.1	15
108	Association Between Response to Etrolizumab and Expression of Integrin α E and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 477-487.e9.	0.6	133

#	ARTICLE	IF	CITATIONS
109	Long-lasting Remission Induced by Syngeneic Haematopoietic Stem Cell Transplantation in a Patient with Refractory Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1122-1124.	0.6	6
110	Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1456-1462.	6.1	56
111	Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. <i>Gastroenterology</i> , 2016, 150, 96-102.	0.6	83
112	Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 389-395.e3.	0.6	40
113	Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 348-354.e17.	2.4	309
114	Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 601-606.	0.6	81
115	MERTK as negative regulator of human T cell activation. <i>Journal of Leukocyte Biology</i> , 2015, 97, 751-760.	1.5	99
116	Identification of Risk Loci for Crohn's Disease Phenotypes Using a Genome-Wide Association Study. <i>Gastroenterology</i> , 2015, 148, 794-805.	0.6	46
117	Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials.. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 66-73.	0.6	9
118	Anrukizumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. <i>Gut</i> , 2015, 64, 894-900.	6.1	137
119	Characterization of Inflammation and Fibrosis in Crohn's Disease Lesions by Magnetic Resonance Imaging. <i>American Journal of Gastroenterology</i> , 2015, 110, 432-440.	0.2	215
120	Regulatory T cells for treatment of Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 315-316.	8.2	4
121	Intraperitoneal Administration of Autologous Tolerogenic Dendritic Cells for Refractory Crohn's Disease: A Phase I Study. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1071-1078.	0.6	135
122	Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 5-15.	1.4	5
123	Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. <i>BMC Gastroenterology</i> , 2015, 15, 14.	0.8	76
124	Development of the Lönnemann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2015, 148, 52-63.e3.	0.6	257
125	Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNF α therapy. <i>Gut</i> , 2015, 64, 233-242.	6.1	123
126	Pancreatitis-Associated Protein Does Not Predict Disease Relapse in Inflammatory Bowel Disease Patients. <i>PLoS ONE</i> , 2014, 9, e84957.	1.1	7

#	ARTICLE	IF	CITATIONS
127	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. <i>Gut</i> , 2014, 63, 1381-1392.	6.1	317
128	Safety and Activity of Dersalazine Sodium in Patients with Mild-to-moderate Active Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2004-2012.	0.9	10
129	Accuracy of Advanced Endoscopy and Fecal Calprotectin for Prediction of Relapse in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1187-1193.	0.9	51
130	Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 240-251.	0.6	89
131	Corrigendum to "Optimising monitoring in the management of Crohn's disease: A physician perspective" [<i>Journal of Crohn's and Colitis</i> volume 7 (2013) 653-669]. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 441.	0.6	0
132	A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1485-1493.e2.	2.4	256
133	Reply to letter on published paper: Improving quality of care in inflammatory bowel disease: What changes can be made today?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1568.	0.6	0
134	A genome-wide association study identifies a novel locus at 6q22.1 associated with ulcerative colitis. <i>Human Molecular Genetics</i> , 2014, 23, 6927-6934.	1.4	39
135	Development of Drugs to Target Interactions Between Leukocytes and Endothelial Cells and Treatment Algorithms for Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2014, 147, 981-989.	0.6	85
136	Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2014, 384, 309-318.	6.3	421
137	Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 927-935.	0.6	117
138	Improving quality of care in inflammatory bowel disease: What changes can be made today?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 919-926.	0.6	65
139	Reply. <i>Gastroenterology</i> , 2014, 146, 869-870.	0.6	0
140	Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, 374-382.e1.	0.6	313
141	Clinical trials in luminal Crohn's disease: A historical perspective. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1339-1350.	0.6	23
142	Evaluation of Responsive Gene Expression as a Sensitive and Specific Biomarker in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 221-229.	0.9	19
143	Optimising monitoring in the management of Crohn's disease: A physician's perspective. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 653-669.	0.6	96
144	Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases. <i>International Journal of Colorectal Disease</i> , 2013, 28, 1281-1286.	1.0	0

#	ARTICLE	IF	CITATIONS
145	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 1-33.	0.6	422
146	Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. <i>Gut</i> , 2013, 62, 1556-1565.	6.1	221
147	Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. <i>Gut</i> , 2013, 62, 967-976.	6.1	208
148	National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 497-509.	0.6	22
149	Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 717-722.	0.6	80
150	Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 958-967.	0.6	13
151	Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 208-212.	0.6	82
152	Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 556-585.	0.6	541
153	New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. <i>Pharmacogenomics</i> , 2013, 14, 631-640.	0.6	20
154	Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease. <i>Gastroenterology</i> , 2013, 145, 766-774.e1.	0.6	221
155	A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at <i>RBX1-EP300</i> . <i>Gut</i> , 2013, 62, 1440-1445.	6.1	42
156	Preface. <i>Digestive Diseases</i> , 2013, 31, 185-185.	0.8	0
157	Smoking does influence disease behaviour and impacts the need for therapy in Crohn's disease in the biologic era. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 752-760.	1.9	73
158	Diagnostic accuracy of magnetic resonance colonography for the evaluation of disease activity and severity in ulcerative colitis: a prospective study. <i>Gut</i> , 2013, 62, 1566-1572.	6.1	61
159	Imaging of the Colon in Inflammatory Bowel Disease: Ready for Prime Time?. <i>Current Drug Targets</i> , 2012, 13, 1252-1260.	1.0	23
160	Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. <i>BMC Gastroenterology</i> , 2012, 12, 108.	0.8	69
161	Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2012, 367, 616-624.	13.9	716
162	Anti-TNF antibody therapy in Crohn's disease: the risk of a switch. <i>Gut</i> , 2012, 61, 169-170.	6.1	10

#	ARTICLE	IF	CITATIONS
163	Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. <i>American Journal of Gastroenterology</i> , 2012, 107, 1770-1776.	0.2	93
164	Rituximab in Active Ulcerative Colitis. <i>Gastroenterology</i> , 2012, 142, 174-176.	0.6	4
165	Adalimumab in Ulcerative Colitis: Can Pharmacodynamics Be Improved Based on Pharmacokinetics?. <i>Gastroenterology</i> , 2012, 142, 176-178.	0.6	7
166	New Imaging Standards for Evaluation of Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2012, 143, 859-862.	0.6	2
167	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 116-131.	0.6	18
168	Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 248-258.	0.6	38
169	Imaging indexes of activity and severity for Crohn's disease: current status and future trends. <i>Abdominal Imaging</i> , 2012, 37, 958-966.	2.0	48
170	MRI of Crohn's disease: from imaging to pathology. <i>Abdominal Imaging</i> , 2012, 37, 387-396.	2.0	22
171	Gram-Negative Enterobacteria Induce Tolerogenic Maturation in Dexamethasone Conditioned Dendritic Cells. <i>PLoS ONE</i> , 2012, 7, e52456.	1.1	29
172	Confocal Endomicroscopy in Celiac Disease. <i>Gastroenterology</i> , 2011, 140, 1097-1099.	0.6	3
173	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 484-498.	0.6	93
174	Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. <i>Gastrointestinal Endoscopy</i> , 2011, 74, 840-848.	0.5	146
175	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1594-1602.	0.2	71
176	Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 113-118.	1.1	114
177	Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis. <i>Current Drug Targets</i> , 2011, 12, 1467-1477.	1.0	0
178	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , 2011, 43, 246-252.	9.4	1,201
179	Mesenchymal stem cell therapy of Crohn's disease: are the far-away hills getting closer?. <i>Gut</i> , 2011, 60, 742-744.	6.1	10
180	Development of the Crohn's disease digestive damage score, the Lönnemann score. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1415-1422.	0.9	496

#	ARTICLE	IF	CITATIONS
181	Magnetic resonance imaging for evaluation of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1759-1768.	0.9	413
182	The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. <i>Gut</i> , 2011, 60, 1068-1075.	6.1	128
183	Probiotic <i>Sonicates</i> Selectively Induce Mucosal Immune Cells Apoptosis through Ceramide Generation via Neutral Sphingomyelinase. <i>PLoS ONE</i> , 2011, 6, e16953.	1.1	23
184	Colonic Crohn's disease: value of magnetic resonance colonography for detection and quantification of disease activity. <i>Abdominal Imaging</i> , 2010, 35, 422-427.	2.0	35
185	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1118-1125.	9.4	2,284
186	New MRI modalities for assessment of inflammatory bowel disease. <i>Gut</i> , 2010, 59, 1308-1309.	6.1	10
187	Stem cell treatment for Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2010, 6, 597-605.	1.3	19
188	Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data. <i>American Journal of Gastroenterology</i> , 2010, 105, 1574-1582.	0.2	201
189	The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 7-27.	0.6	1,050
190	The 2-Phase Model of Crohn's Disease: From Immune Defect to Hyperresponse. <i>Gastroenterology</i> , 2010, 138, 1204-1206.	0.6	1
191	Toward a Safer Use of Thiopurines in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2010, 138, 1618-1620.	0.6	0
192	Optimizing Care of Hereditary Hemorrhagic Telangiectasia. <i>Gastroenterology</i> , 2010, 138, 2014-2016.	0.6	1
193	Is Lack of Education a Mechanism Driving Loss of Tolerance in Crohn's Disease?. <i>Gastroenterology</i> , 2010, 139, 1056-1058.	0.6	0
194	Telomerase mRNA expression and immunohistochemical detection as a biomarker of malignant transformation in patients with inflammatory bowel disease. <i>Gastroenterology & Hepatology</i> , 2010, 33, 288-296.	0.2	4
195	Response to Chao and Mulani. <i>American Journal of Gastroenterology</i> , 2009, 104, 2354-2355.	0.2	1
196	Role of 3.0-T MR Colonography in the Evaluation of Inflammatory Bowel Disease. <i>Radiographics</i> , 2009, 29, 701-719.	1.4	52
197	Mechanisms underlying the beneficial effects of stem cell therapies for inflammatory bowel diseases. <i>Gut</i> , 2009, 58, 898-900.	6.1	15
198	Defective IL-10 production in severe phenotypes of Crohn's disease. <i>Journal of Leukocyte Biology</i> , 2009, 85, 896-903.	1.5	56

#	ARTICLE	IF	CITATIONS
199	Risk factors and characteristics of extent progression in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1320-1325.	0.9	63
200	VEGF-A Links Angiogenesis and Inflammation in Inflammatory Bowel Disease Pathogenesis. <i>Gastroenterology</i> , 2009, 136, 585-595.e5.	0.6	289
201	Defects in Autophagy Induce Alterations in the Secretory Pathway and Proinflammatory Signaling of Paneth Cells. <i>Gastroenterology</i> , 2009, 137, 1527-1529.	0.6	2
202	Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study. <i>American Journal of Gastroenterology</i> , 2009, 104, 57-63.	0.2	130
203	Cell therapies for inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 321-324.	1.4	5
204	Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review. <i>American Journal of Gastroenterology</i> , 2009, 104, 760-767.	0.2	564
205	Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 347-352.	0.9	48
206	Health-related quality of life in inflammatory bowel disease patients: The role of psychopathology and personality. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 977-983.	0.9	80
207	European evidence-based Consensus on the management of ulcerative colitis: Special situations. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 63-92.	0.6	206
208	Corrigendum to "European evidence-based consensus on the management of ulcerative colitis: Special situations" [<i>J Crohn's & Colitis</i> 2 (2008) 63-92]. <i>Journal of Crohn's and Colitis</i> , 2008, 2, 191.	0.6	1
209	Time course of anti-inflammatory effect of low-dose radiotherapy: Correlation with TGF- β 1 expression. <i>Radiotherapy and Oncology</i> , 2008, 86, 399-406.	0.3	40
210	A Multicenter, Randomized, Double-Blind Trial of Everolimus Versus Azathioprine and Placebo to Maintain Steroid-Induced Remission in Patients With Moderate-to-Severe Active Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 2284-2292.	0.2	87
211	Are we giving biologics too late? The case for early versus late use. <i>World Journal of Gastroenterology</i> , 2008, 14, 5523.	1.4	21
212	Efficacy of an inhibitor of adhesion molecule expression (GI270384X) in the treatment of experimental colitis. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G739-G748.	1.6	11
213	The classics in perspective. <i>Gut</i> , 2007, 56, 1184-1186.	6.1	1
214	Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. <i>Respiratory Physiology and Neurobiology</i> , 2007, 155, 93-96.	0.7	85
215	Use of Acid-Suppressing Drugs and the Risk of Bacterial Gastroenteritis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 1418-1423.	2.4	118
216	Risk of Irritable Bowel Syndrome After an Episode of Bacterial Gastroenteritis in General Practice: Influence of Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 465-469.	2.4	74

#	ARTICLE	IF	CITATIONS
217	Psychometric properties of the original Inflammatory Bowel Disease Questionnaire, a Spanish version. <i>Gastroenterología Y Hepatología</i> , 2007, 30, 212-218.	0.2	7
218	Crohn's Disease. <i>Drugs</i> , 2007, 67, 2511-2537.	4.9	60
219	Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. <i>Journal of Clinical Investigation</i> , 2007, 117, 1951-1960.	3.9	105
220	Acute Gastroenteritis Is Followed by an Increased Risk of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2006, 130, 1588-1594.	0.6	351
221	Anti-VCAM-1 Antibodies did not Protect against Ischemic Damage Either in Rats Or in Mice. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 421-432.	2.4	104
222	Anti-inflammatory effects of low-dose radiotherapy in an experimental model of systemic inflammation in mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 560-567.	0.4	73
223	<i>Lactobacillus casei</i> prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G1155-G1162.	1.6	23
224	Life Events and Inflammatory Bowel Disease Relapse: A Prospective Study of Patients Enrolled in Remission. <i>American Journal of Gastroenterology</i> , 2006, 101, 775-781.	0.2	74
225	Crohn's Disease Patients Carrying Nod2/CARD15 Gene Variants Have an Increased and Early Need for First Surgery due to Stricture Disease and Higher Rate of Surgical Recurrence. <i>Annals of Surgery</i> , 2005, 242, 693-700.	2.1	163
226	Protective effect of superoxide dismutase in radiation-induced intestinal inflammation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1159-1166.	0.4	24
227	P-selectin mediates leukocyte rolling in concanavalin-A-induced hepatitis. <i>Liver International</i> , 2005, 25, 1053-1060.	1.9	6
228	Down-Regulation of Endothelial Adhesion Molecules and Leukocyte Adhesion by Treatment with Superoxide Dismutase Is Beneficial in Chronic Immune Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 872-882.	0.9	44
229	Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. <i>Journal of Leukocyte Biology</i> , 2004, 76, 537-544.	1.5	141
230	Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. <i>Journal of Leukocyte Biology</i> , 2004, 75, 214-223.	1.5	33
231	Direct evidence of leukocyte adhesion in arterioles by angiotensin II. <i>Blood</i> , 2004, 104, 402-408.	0.6	153
232	Relative roles of ICAM-1 and VCAM-1 in the pathogenesis of experimental radiation-induced intestinal inflammation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 264-273.	0.4	76
233	Fructose-1,6-biphosphate and nucleoside pool modifications prevent neutrophil accumulation in the reperfused intestine. <i>Journal of Leukocyte Biology</i> , 2003, 73, 74-81.	1.5	12
234	Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract. <i>Current Pharmaceutical Design</i> , 2003, 9, 2253-2266.	0.9	60

#	ARTICLE	IF	CITATIONS
235	Nitric Oxide Supplementation Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice. <i>Laboratory Investigation</i> , 2002, 82, 597-608.	1.7	35
236	¹²³ Iodine-labelled anti-VCAM-1 antibody scintigraphy in the assessment of experimental colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 31-38.	0.8	18
237	Role of P-selectin in radiation-induced intestinal inflammatory damage. <i>International Journal of Cancer</i> , 2001, 96, 99-109.	2.3	35
238	Brain Endothelial Adhesion Molecule Expression in Experimental Colitis. <i>Microcirculation</i> , 2001, 8, 105-114.	1.0	11
239	VCAM-1, but Not ICAM-1 or MAdCAM-1, Immunoblockade Ameliorates DSS-Induced Colitis in Mice. <i>Laboratory Investigation</i> , 2000, 80, 1541-1551.	1.7	172
240	H ₂ O ₂ and PARS mediate lung P-selectin upregulation in acute pancreatitis. <i>Free Radical Biology and Medicine</i> , 2000, 28, 1286-1294.	1.3	29
241	Optimization of technetium-99m-HMPAO leukocyte scintigraphy in evaluation of active inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1828-1835.	1.1	27
242	Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G734-G743.	1.6	72
243	Influence of dose-rate on inflammatory damage and adhesion molecule expression after abdominal radiation in the rat. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 45, 1011-1018.	0.4	31
244	Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. <i>British Journal of Pharmacology</i> , 1999, 126, 537-550.	2.7	226
245	Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat. <i>Hepatology</i> , 1999, 30, 445-453.	3.6	21
246	Adhesion molecules in inflammatory bowel disease. <i>Pathophysiology</i> , 1999, 5, 271-282.	1.0	3
247	Role of P-Selectin and ICAM-1 in Pancreatitis-Induced Lung Inflammation in Rats. <i>Annals of Surgery</i> , 1999, 230, 792.	2.1	79
248	ICAM-1 upregulation in distant tissues after hepatic ischemia/reperfusion: A clue to the mechanism of multiple organ failure. <i>Journal of Pediatric Surgery</i> , 1998, 33, 350-353.	0.8	46
249	Leukocyte-endothelial cell interactions: Molecular mechanisms and implications in gastrointestinal disease. <i>Gastroenterology</i> , 1998, 114, 1066-1090.	0.6	337
250	Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia. <i>Transfusion</i> , 1997, 37, 573-576.	0.8	49
251	Role of leukocyte-endothelial cell adhesion in radiation-induced microvascular dysfunction in rats. <i>Gastroenterology</i> , 1995, 108, 1761-1769.	0.6	109
252	Time-course changes in gastric mucosal blood perfusion following portal vein constriction in rats. <i>Journal of Hepatology</i> , 1995, 23, 193-198.	1.8	13

#	ARTICLE	IF	CITATIONS
253	Anemia increases gastric blood flow in noncirrhotic and cirrhotic patients. <i>Gastrointestinal Endoscopy</i> , 1995, 42, 403-407.	0.5	16
254	Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1994, 19, 55-60.	3.6	45
255	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. <i>Hepatology</i> , 1994, 20, 336-341.	3.6	52
256	Gastric microcirculatory changes of Portal-hypertensive rats can be attenuated by long-term Estrogen-progestagen treatment. <i>Hepatology</i> , 1994, 20, 1261-1270.	3.6	37
257	Neonatal capsaicin treatment does not prevent splanchnic vasodilatation in portal-hypertensive rats. <i>Hepatology</i> , 1994, 20, 1609-1614.	3.6	15
258	Effects of chronic normovolemic anemia on gastric microcirculation and ethanol-induced gastric damage in rats. <i>Digestive Diseases and Sciences</i> , 1994, 39, 751-757.	1.1	5
259	Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal-hypertensive gastropathy. <i>Hepatology</i> , 1994, 20, 336-341.	3.6	4
260	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1993, 17, 213-218.	3.6	41
261	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. <i>Hepatology</i> , 1993, 18, 628-634.	3.6	44
262	Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 1993, 17, 48-53.	1.4	33
263	Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal-hypertensive anesthetized rats. <i>Hepatology</i> , 1993, 18, 628-634.	3.6	4
264	Intestinal Ischemia. , 0, , 2811-2830.		0
265	MRI scoring indices for evaluation of disease activity and severity in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	1.5	0
266	Intestinal Ischemia. , 0, , 858-877.		1